Santhera today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan and Uzbekistan, for the treatment of Duchenne muscular dystrophy (DMD) in patients two years of age and older.
Biomedica was originally appointed as a distributor for AGAMREE® in October 2025. Under the expanded agreement, Biomedica will be responsible for distribution in the additional five markets, while Santhera will continue to receive a percentage of net sales in line with the terms of the original agreement. Approximately 2,000 patients are living with DMD across these additional countries, where treatment options have historically been largely limited to standard corticosteroids. The expanded agreement creates a pathway to making AGAMREE® available to these patients. Read More: What is AGAMREE (Vamorolone)?
